Drug-Drug Interactions

Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have bee...

Celý popis

Uloženo v:

Podrobná bibliografie
Médium:	Online
Jazyk:	angličtina
Vydáno:	MDPI - Multidisciplinary Digital Publishing Institute 2022
Témata:	tadalafil ticagrelor drug-drug interaction pharmacokinetics plasma concentration CYP3A4 Loxoprofen CYP3A Dexamethasone Ketoconazole CYP2D6 O-desmethyltramadol physiologically-based pharmacokinetics tramadol (‒)-sophoranone CYP2C9 potent inhibition in vitro in vivo drug interaction low permeability high plasma protein binding biflavonoid cytochrome P450 drug interactions selamariscina A uridine 5′-diphosphoglucuronosyl transferase tissue-specific systemic exposure P-glycoprotein (P-gp) organic anion transporting polypeptide 1A2 (OATP1A2) Rumex acetosa fexofenadine chronic kidney disease drug–drug interactions polypharmacy adverse drug reactions Lexicomp subset analysis signal detection algorithms spontaneous reporting systems mechanism-based inhibition competitive inhibition non-competitive inhibition substrate inhibitor cytochromes P450 OATP1B1 OATP1B3 tyrosine kinase inhibitors drug-drug interactions migraine lasmiditan gepants monoclonal antibodies CYP1A1 CYP1A2 drug–drug interaction expression metabolism regulation drug transporter ubiquitination ixazomib DDI computational prediction in silico QSAR drug metabolism ADME CYP metabolic DDI P450 1A2 2B6 2C19 2C8 2C9 2D6 3A4 thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general thema EDItEUR::P Mathematics and Science::PS Biology, life sciences
On-line přístup:	ONIX_20220111_9783036520353_606
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.

Drug-Drug Interactions

Podobné jednotky